Mallinckrodt Baker and Rubicon Research Sign Agreement for Performance Excipient...

Mallinckrodt Baker and Rubicon Research Sign Agreement for Performance Excipient Development

Companies collaborate to provide leading-edge drug delivery
technology
PHILLIPSBURG, N.J.--(Business Wire)--
Covidien (NYSE: COV, BSX: COV), a leading global provider of
healthcare products, today announced that its Mallinckrodt Baker
business has entered into a licensing and commercialization agreement
with drug development research specialist Rubicon Research. Following
the July 2008 launch of its PanExcea(TM) performance excipient,
Mallinckrodt Baker is teaming with Rubicon Research to expand its
performance excipient platform. The two companies will develop and
launch additional products under the PanExcea brand through 2009.

"This partnership allows Mallinckrodt Baker to take a global
leadership role in the development and commercialization of
performance excipients," said Paul Smaltz, Vice President, Global
Marketing for Mallinckrodt Baker. "As Mallinckrodt Baker expands its
presence as a supplier of performance excipients throughout the
pharmaceutical landscape, we believe Rubicon Research's
industry-leading expertise in formulation and drug delivery technology
will assist us in providing leading-edge products that enable faster,
more cost-efficient drug development and manufacturing."

Under the agreement, Rubicon Research will provide technology
development and formulation expertise to Mallinckrodt Baker. An
established contract research organization with an extensive network
of customers in the global pharmaceutical industry, Rubicon Research
is focused on oral solid dosage forms and dispersed systems. It also
has expertise in the design and implementation of customized delivery
systems.

"This collaboration with Mallinckrodt Baker enhances our position
as a global comprehensive solution provider for diverse drug
development challenges," said Pratibha Pilgaonkar, CEO of Rubicon
Research. "Mallinckrodt Baker's understanding of the global
pharmaceutical markets will spur Rubicon's research in areas of
performance excipients and related technologies and its extensive
expertise in pharmaceutical manufacturing and commercial know-how
helps add value and worldwide access to Rubicon's technologies."

As a leading global manufacturer of fine chemical process
intermediates and excipients for the pharmaceutical and
biopharmaceutical markets, Mallinckrodt Baker has two highly respected
global brand names in the pharmaceutical industry, J.T.Baker(R) and
Mallinckrodt(R) chemicals. Offering Beaker-to-Bulk packaging
flexibility and consistently high-quality products supported by
ICH-Q7A systems design, Mallinckrodt Baker excels in application-based
technology innovations and product solutions.

For more information about Mallinckrodt Baker's PanExcea
performance excipient, visit www.mallbaker.com.

ABOUT MALLINCKRODT BAKER

Mallinckrodt Baker is a manufacturer of high purity chemicals and
related products and services sold under two well-known and respected
brand names - J.T.Baker(R) and Mallinckrodt(R) Chemicals. These
products are widely used in research and quality control laboratories,
microelectronics, environmental testing laboratories and universities,
and for manufacturing in the pharmaceutical, biotechnology, and other
industrial markets. Based in Phillipsburg, New Jersey, Mallinckrodt
Baker is part of Covidien.

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that
creates innovative medical solutions for better patient outcomes and
delivers value through clinical leadership and excellence. Covidien
manufactures, distributes and services a diverse range of
industry-leading product lines in four segments: Medical Devices,
Imaging Solutions, Pharmaceutical Products and Medical Supplies. With
2007 revenue of nearly $9 billion, Covidien has more than 42,000
employees worldwide in 57 countries, and its products are sold in over
130 countries. Please visit www.covidien.com to learn more about our
business.

Trademarks are owned by Mallinckrodt Baker, Inc., unless otherwise
noted.

Mallinckrodt(R) is a trademark of Mallinckrodt Inc.

Mallinckrodt Baker, Inc.
Erica Abbett, 314-654-3247
erica.abbett@covidien.com
or
Covidien
Coleman Lannum, CFA
Vice President - Investor Relations
508.452.4343
cole.lannum@covidien.com

Copyright Business Wire 2008